Baird Incrementally Positive on Biogen (BIIB) Nusinersen Data; PT to $284
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
August 1, 2016 7:30 AM EDTBiogen Intends to File Marketing Applications for Nusinersen with Regulatory Authorities in the Coming Months
Biogen Exercises Option to Develop and Commercialize Nusinersen Globally
Companies to Host Webcast Today at 9:00 a.m. EDT to Provide Program Update
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)-- Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS) today announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen in... More
